Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors

• Shanghai Fosun Pharma unit Shanghai Fosun Pharmaceutical Industrial Development won China clearance for a new Luvometinib Tablets indication.
• Label expansion covers adult NF1 patients with symptomatic plexiform neurofibromas not suitable for complete surgical removal.
• Luvometinib is a self-developed MEK1/2 inhibitor; Fosun recorded about RMB 714 million in R&D spending as of July 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260903-12318635), on September 03, 2026, and is solely responsible for the information contained therein.